The same phenomenon was also observed in melanoma patients who acquired resistance to PD-1 blockade due to a homozygous truncating mutation in β2M, which prohibited the major histocompatibility complex (MHC) class I surface expression level (13). This evidence concerns the gene PDCD1 and melanoma.